These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

914 related articles for article (PubMed ID: 11543951)

  • 1. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
    Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
    Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone.
    Beattie DT; Cheruvu M; Mai N; O'Keefe M; Johnson-Rabidoux S; Peterson C; Kaufman E; Vickery R
    Naunyn Schmiedebergs Arch Pharmacol; 2007 May; 375(3):205-20. PubMed ID: 17340127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anatomical distribution of mu, delta, and kappa opioid- and nociceptin/orphanin FQ-stimulated [35S]guanylyl-5'-O-(gamma-thio)-triphosphate binding in guinea pig brain.
    Sim LJ; Childers SR
    J Comp Neurol; 1997 Oct; 386(4):562-72. PubMed ID: 9378852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inverse agonism by Dmt-Tic analogues and HS 378, a naltrindole analogue.
    Labarre M; Butterworth J; St-Onge S; Payza K; Schmidhammer H; Salvadori S; Balboni G; Guerrini R; Bryant SD; Lazarus LH
    Eur J Pharmacol; 2000 Oct; 406(1):R1-3. PubMed ID: 11011049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment.
    Liu JG; Prather PL
    Mol Pharmacol; 2001 Jul; 60(1):53-62. PubMed ID: 11408600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?
    Bart G; Schluger JH; Borg L; Ho A; Bidlack JM; Kreek MJ
    Neuropsychopharmacology; 2005 Dec; 30(12):2254-62. PubMed ID: 15988468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid and cannabinoid receptors share a common pool of GTP-binding proteins in cotransfected cells, but not in cells which endogenously coexpress the receptors.
    Shapira M; Vogel Z; Sarne Y
    Cell Mol Neurobiol; 2000 Jun; 20(3):291-304. PubMed ID: 10789829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
    Wang D; Sun X; Sadee W
    J Pharmacol Exp Ther; 2007 May; 321(2):544-52. PubMed ID: 17267582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential binding properties of oripavines at cloned mu- and delta-opioid receptors.
    Lee KO; Akil H; Woods JH; Traynor JR
    Eur J Pharmacol; 1999 Aug; 378(3):323-30. PubMed ID: 10493109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective mu/kappa antagonist in the [35S]-GTP-gamma-S functional binding assay.
    Romero DV; Partilla JS; Zheng QX; Heyliger SO; Ni Q; Rice KC; Lai J; Rothman RB
    Synapse; 1999 Nov; 34(2):83-94. PubMed ID: 10502307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
    Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute and chronic effects of opioids on delta and mu receptor activation of G proteins in NG108-15 and SK-N-SH cell membranes.
    Breivogel CS; Selley DE; Childers SR
    J Neurochem; 1997 Apr; 68(4):1462-72. PubMed ID: 9084416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid peptide receptor studies. 10. Nor-BNI differentially inhibits kappa receptor agonist-induced G-protein activation in the guinea pig caudate: further evidence of kappa receptor heterogeneity.
    Heyliger SO; Jackson C; Rice KC; Rothman RB
    Synapse; 1999 Dec; 34(4):256-65. PubMed ID: 10529720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of opioid agonists on G protein expression in CHO cells expressing cloned human opioid receptors.
    Xu H; Wang X; Partilla JS; Bishop-Mathis K; Benaderet TS; Dersch CM; Simpson DS; Prisinzano TE; Rothman RB
    Brain Res Bull; 2008 Sep; 77(1):49-54. PubMed ID: 18639745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
    Alt A; McFadyen IJ; Fan CD; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2001 Jul; 298(1):116-21. PubMed ID: 11408532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoradiographic distribution of mu-, delta- and kappa 1-opioid stimulated [35S]guanylyl-5'-O-(gamma-thio)-triphosphate binding in human frontal cortex and cerebellum.
    Platzer S; Winkler A; Schadrack J; Dworzak D; Tölle TR; Zieglgänsberger W; Spanagel R
    Neurosci Lett; 2000 Apr; 283(3):213-6. PubMed ID: 10754225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors.
    Liu JG; Prather PL
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1070-9. PubMed ID: 12183665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception.
    Stevenson GW; Folk JE; Linsenmayer DC; Rice KC; Negus SS
    J Pharmacol Exp Ther; 2003 Dec; 307(3):1054-64. PubMed ID: 14557380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.
    Healy JR; Bezawada P; Shim J; Jones JW; Kane MA; MacKerell AD; Coop A; Matsumoto RR
    ACS Chem Neurosci; 2013 Sep; 4(9):1256-66. PubMed ID: 23713721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.